https://pubmed.ncbi.nlm.nih.gov/35456276/
Phase I Targeted Combination Trial of Sorafenib and GW5074 in Patients with Advanced Refractory...
Co-administration therapy of GW5074 and sorafenib demonstrated a favorable safety profile and showed anti-tumor activity in a variety of tumor types. However,...